Prolactinoma
Also known as: Prolactin-secreting pituitary adenoma, Lactotroph adenoma, Prolactin-producing pituitary tumour
A prolactinoma is a prolactin-secreting pituitary tumour that can affect reproductive function and, when larger, cause pressure-related symptoms. Endocrinology-led care includes monitoring serum prolactin, assessment of other pituitary hormones, and imaging or visual assessment as indicated. Dopamine agonists are established first-line therapy; inadequate response requires specialist reassessment. Traditional Chinese Medicine (TCM) may be considered only as adjunctive, symptom-focused care, not tumour treatment. The supplied records contain no clinical acupuncture trials or evidence establishing herbal formula efficacy for prolactinoma. Paeoniflorin findings concern rats and cultured cells, not demonstrated patient benefit. The breast cancer case cannot establish general treatment compatibility, and the editorial supplies no assessable abstract evidence.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Maintain a comprehensive record of headaches, visual symptoms, menstrual changes, sexual symptoms, and adverse medication reactions for endocrine review.
- •Adhere to regular sleep hygiene and stress-reduction protocols, though stress is not an established driver of adenoma progression.
- •Ensure balanced nutritional intake and tolerable physical activity; discuss bone health with the medical team if reproductive hormone deficiency is present.
- •Consult the endocrine team prior to conception planning and avoid independent initiation of herbal products or modification of prescribed medication.
Cautions & Contraindications
- •Do not stop or reduce prescribed dopamine agonists because acupuncture or herbs are being used. Record 2 identifies dopamine agonists as first-line treatment; its cell findings do not support a replacement treatment.[]
- •Do not extrapolate paeoniflorin results to the safety or efficacy of peony-containing formulas in humans, pregnancy or breastfeeding. Record 4 reports rat and cell experiments, not clinical formula trials or interaction studies.[]
- •Concurrent chemotherapy, targeted therapy or radiotherapy requires oncology and pharmacy review before herbal treatment, and procedural clearance where cytopenias or infection risks exist. Record 1 reports one coordinated conventional-treatment case and provides no evidence of herbal or acupuncture compatibility.[]
- •Do not offer decitabine or an epigenetic-targeting strategy as adjunctive prolactinoma care on the basis of record 2: the reported work is preclinical and does not establish patient benefit or clinical safety.[]
When to reassess or seek care again
Review any adjunctive trial after 2–4 weeks using baseline and follow-up symptom ratings, headache days, sleep quality, digestive symptoms and adverse effects. Prolactin tests, imaging and visual-field reviews remain on the endocrine team's schedule; symptom improvement is not evidence of tumour response. Stop or revise adjunctive care if there is no meaningful symptomatic benefit, and refer promptly for worsening symptoms, suspected medicine intolerance or biochemical or imaging deterioration. Emergency symptoms require immediate assessment, not the scheduled review.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- AME case reports · 2026
- Frontiers in endocrinology · 2026
- Frontiers in oncology · 2026
- Toxicology and applied pharmacology · 2025
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
